MiNK Therapeutics (NASDAQ:INKT) & Humacyte (NASDAQ:HUMA) Critical Comparison

MiNK Therapeutics (NASDAQ:INKT) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings.

Valuation and Earnings

This table compares MiNK Therapeutics and Humacyte”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$22.46 million	($0.60)	-1.25
Humacyte	$1.57 million	412.62	-$110.78 million	($1.00)	-5.44

MiNK Therapeutics has higher earnings, but lower revenue than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 17.8% of MiNK Therapeutics shares are owned by insiders. Comparatively, 23.1% of Humacyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk and Volatility

MiNK Therapeutics has a beta of 0.06, suggesting that its stock price is 94% less volatile than the S&P 500. Comparatively, Humacyte has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500.

Profitability

This table compares MiNK Therapeutics and Humacyte’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-233.85%
Humacyte	N/A	-942.81%	-79.04%

Analyst Recommendations

This is a summary of current ratings and recommmendations for MiNK Therapeutics and Humacyte, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	0	0	1	0	3.00
Humacyte	0	1	4	1	3.00

MiNK Therapeutics presently has a consensus price target of $9.00, indicating a potential upside of 1,100.00%. Humacyte has a consensus price target of $9.80, indicating a potential upside of 80.15%. Given MiNK Therapeutics’ higher probable upside, research analysts plainly believe MiNK Therapeutics is more favorable than Humacyte.

Summary

Humacyte beats MiNK Therapeutics on 7 of the 12 factors compared between the two stocks.

About MiNK Therapeutics

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

About Humacyte

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.